This site is intended for US audiences only.

This site is intended for US audiences only.

REVLIMID is a prescription medicine used to treat adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL) in combination with a rituximab product, and who have previously been treated for their FL or MZL. FL and MZL are types of cancer of white blood cells called B-cell lymphocytes that are found in the lymph nodes and spleen. REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.

The REMS Companion App

Easily access the
Lenalidomide REMS program.

Download now

Get involved.
Stay informed.

Hypothetical R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma and a loved one

A network of support

Continuing to learn more about your disease and connecting with others is a great way to take an active role in your care. These organizations provide additional information about follicular lymphoma and marginal zone lymphoma and can help you or your loved ones find a local support group.

Support groups

Lymphoma Research Foundation


American Cancer Society

1-800-ACS-2345 (1-800-227-2345)

This list of independent organizations is provided as an additional resource that may help in obtaining information related to follicular and marginal zone lymphoma. This list does not indicate endorsement by Celgene Corporation, a Bristol Myers Squibb company, of an organization or its communications.